Mach7 and 3D Medical to merge

Mach7 Technologies, a global provider of enterprise medical image management solutions, and 3D Medical Limited have signed a definitive agreement to merge. The merger will provide access via public capital markets for Mach7 while preserving corporate self-determination with regard to mission and product roadmap. Upon approval and completion of the agreement, the merged entity will be publicly listed on the Australian stock exchange (ASX) and will trade as “Mach7 Technologies Ltd”.
Mach7 and 3DM enjoy a strong working relationship in 3DM’s capacity as the exclusive reseller of the Mach7 image management solutions for hospitals and radiology clinics in Australia and New Zealand.
Mach7 Technologies is a global provider of enterprise image management systems, enabling healthcare enterprises to easily identify, connect, and share diagnostic image and patient care intelligence where and when needed. The solutions improve patient care, compliance, and clinician satisfaction. Frost & Sullivan recently named Mach7 Technologies Medical Imaging Informatics Company of the Year in the Asia Pacific region.
Mach7’s global customer base includes leading healthcare organisations such as Penn Medicine, Raffles Hospital, and Massachusetts General and has operations in 10 countries. Mach7 has 43 employees, the majority located in Burlington, Vermont and generates strong contractual cash flow from software licenses and support agreements.
Both 3DM and Mach7 intend to maintain their respective workforce in engineering, customer sales, support, marketing, and service relationships without alteration.
“Our commitment to customer-driven design is the core of our culture,” commented Albert Liong, Chief Executive Officer, Mach7. “We will remain a nimble company focused on providing the most innovative enterprise imaging platform in the world. Access to new capital will enable us to surpass business and product roadmap goals in a shorter time frame and to better serve our customers. Mach7 has enjoyed substantial growth in recent years, and we feel this will be enhanced with access to the public capital market. Australian investors appreciate world leading healthcare technology, and we look forward to this new phase as we continue to build our global presence.”
“We are delighted to have secured an agreement to bring our companies together,” noted Dr Nigel Finch, Chairman of 3DM. “We have enjoyed a close working relationship with Mach7 and admire their outstanding success in the US and Asia. This transaction delivers a material revenue boost to 3DM and importantly allows 3DM shareholders to benefit from the ownership of best-in-breed healthcare imaging intellectual property. The transaction will drive earnings and transform the combined entity into a global operation, allowing significant opportunities to scale 3DM’s value-adding data activities to leading healthcare institutions globally.”
Mach7 has locations in the US, Asia, Australia, and the Middle East.